Teleperformance: Majorel Integration And AI Are Well On Track; Buy Confirmed
Teleperformance continues to show strong fundamentals in H1. The company's AI initiatives and Majorel acquisition are future earnings growth. Majorel integration might yield significant cost synergies ahead. Teleperformance organic growth was beat for the 2nd consecutive quarter. The company confirmed its 2024 guidance, and we reiterate our buy rating.
Arthur J. Gallagher: Strong Growth Expectations And Track Record
Arthur J. Gallagher shows strong revenue and profit growth, with a CAGR of 8.5% in revenue and 24.4% in EPS over the past 4 years. The company benefits from a consistent revenue stream, primarily from its insurance brokerage segment, and has a solid track record of organic growth and acquisitions. Despite a lower dividend yield, Arthur J. Gallagher reinvests profits for growth, making it less attractive for income investors compared to Marsh & McLennan.
Nvidia Beats Q2 Estimates, But Stock Slips—Is AI-Driven Growth Still on Track?
Despite beating Q2 earnings estimates, Nvidia's stock drops 2%. Investors eye ambitious Q3 forecasts, signaling potential for sustained AI-driven growth.
Wall Street On Track For Weak Start As Anticipation For Nvidia Earnings Drives Traders To Sidelines: Strategist Flags Shift From Volatile Tech Stocks To Good Dividend-Paying Bets
U.S. stocks are on track for a jittery start as traders brace for a few market-moving catalysts that will pan out over the next few sessions. The index futures were narrowly mixed in early trading.
Roivant Sciences: Inherently Risky Business Model, But Track Record Impresses
Roivant Sciences stock has risen significantly since my initial coverage in 2022, with a positive market response to fiscal year 2025 Q1 earnings. Roivant operates by creating "nimble subsidiaries to develop and commercialize medicines", with a focus on unearthing strong drug candidates for lucrative exits. Key drugs in Roivant's pipeline include VTAMA, Batoclimab, and Breproctinib, each facing competition and uncertainties in their respective markets.
Stella-Jones: Tying Up A Solid Q2 And On Track For A Good Year
Stella-Jones is a profitable company in the Materials sector manufacturing railway ties and utilities poles, with consistent sales growth and strong EBITDA margins. The company's core segments of railway ties and utility poles are performing well, with increased sales and profitability. Despite solid performance, valuation concerns, and potential headwinds in the railway, tie segment may impact future growth, making shares a 'hold' for now.
Retail Sales, Jobless Claims Ease Recession Fears, Fed Rate Cut On Track; S&P 500 Jumps
Retail sales and other economic data eased recession fears while keeping a Fed rate cut on track. The S&P 500 jumped.
3 Long-Term Stocks on Track to Double (or More) by 2032
Investing in the stock market for the long term is always the most sound way to avoid losing money. However, identifying long-term stocks with robust business models and little risk can be somewhat tricky.
Starz & BritBox Launching New Bundle, Lionsgate On Track To Split By Year End, CEO Says
Starz and BBC Studios' BritBox will come together on a new bundle next quarter as streamers big and small continue to pair up, said Lionsgate CEO Jon Feltheimer. Starz' strong core demos “make it a bundling partner of choice,” he added on a call after the company reported earnings for the June quarter.
Rivian Stock Drops, but the Electric Vehicle (EV) Maker Remains on Track to Achieve a Gross Profit in Q4
First-quarter revenue edged up 3% year over year, which was good enough to beat Wall Street's consensus estimate of 1% growth. Adjusted loss was $1.13 per share, narrower than the loss of $1.21 per share analysts had expected.
3 Biotech Stocks on Track for 50% Returns (or More) by 2028
The biotech industry, often recognized for its rapid innovation, can set investors up for outsized returns in the stock market. However, not all biotech companies have the capability of doing so.
Gildan Is Back On Track And Has Good Plans, The Stock Is Fairly Valued
Gildan Activewear Inc.'s Q2 2024 results were positive, with expected growth and increased market share. The company has levers to solidify its leading market position in the industry. Hold rating on the stock has been maintained since March 2024, with a positive outlook for future performance.
